Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who have been diagnosed with small cell lung cancer (SCLC), confirmed through a tissue or cell sample test
• People whose SCLC continued to grow or came back after receiving a first round of platinum-based chemotherapy
• People who have at least one tumour that can be measured on a scan, according to standard measurement guidelines
• People who are generally well enough to carry out light activity and care for themselves (a standard health performance rating of 0 or 1 on a scale used by doctors)
• People with a life expectancy of more than 12 weeks
• Women who are not pregnant at the time of screening, or who are confirmed as not able to become pregnant
• People who are willing and able to use appropriate contraception throughout the study
• People who have given their written agreement to take part before any study procedures begin

Who may not be able to join:

• People with a mixed type of SCLC, a history of SCLC that changed from another lung cancer type, or SCLC that has since changed into non-small cell lung cancer (NSCLC)
• People who received their last chemotherapy treatment 30 days or fewer before joining the study
• People who have previously been treated with therapies that target a protein called B7-H3
• People who have previously received a type of chemotherapy called a topoisomerase I inhibitor, including certain antibody-drug treatments that contain one
• People who have not waited long enough since their last treatment before joining the study, as set out in the study guidelines (confirm with trial site)
• People with brain metastases (cancer that has spread to the brain) that are untreated or causing symptoms, with some exceptions defined in the study guidelines (confirm with trial site)
• People who still have unresolved side effects from previous cancer treatment that remain above a mild level, with some exceptions (confirm with trial site)
• People with a history of another cancer, with some exceptions defined in the study guidelines (confirm with trial site)
• People whose bone marrow, liver, kidneys, or other organs are not functioning at a sufficient level
• People with signs of heart or blood vessel risk factors
• People with serious or uncontrolled heart or blood vessel disease
• People with severe or uncontrolled diabetes
• People with severe or uncontrolled high blood pressure
• People who have had significant or obvious bleeding in the month before joining the study
• People who have had a serious blood clot in an artery or vein within the 3 months before joining the study
• People who have had a serious infection within the 4 weeks before joining the study
• People who have been taking steroid medication throughout their body (not just a cream or inhaler) in the 30 days before joining the study, with some exceptions (confirm with trial site)
• People with an active infectious disease at the time of joining
• People with current liver brain disease (hepatic encephalopathy), a liver-kidney syndrome, or moderate to severe liver scarring (cirrhosis rated Child-Pugh Grade B or worse)
• People with a history of scarring lung disease, lung inflammation caused by immunotherapy, or moderate to severe lung disease
• People with a history of severe nerve damage or serious mental health disorders
• Women who are able to become pregnant, are currently breastfeeding or plan to breastfeed during the study, or plan to become pregnant during the study
• People who received a vaccine or had any allergic reaction in the 4 weeks before joining the study (confirm with trial site)
• People with a history of serious allergic reactions or serious reactions to infusions, or allergies to proteins derived from human or mouse sources used in treatments
• People with a known allergy to any ingredient in the study drug HS-20093, topoisomerase I inhibitors, or the comparison drug Topotecan

Important: Always verify eligibility with the trial site directly before applying.